Immunohistochemistry and Ancillary Pathology Testing Reimbursement
This document governs reimbursement policy for immunohistochemistry and related ancillary pathology testing for Blue Cross Blue Shield - Tennessee members; it outlines evidence references and that the policy was adopted effective 7/1/2023.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Adoption
References and policy adoption note
This section lists the scientific references and notes the policy adoption effective date; it does not contain itemized coverage criteria.
ALL of the following
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.